Suzhou, China – July 2026 – Jiaxing Jingyin Biotechnology Co., Ltd., the parent company of Beijing OKVD Biological Technology Co., Ltd., made a powerful debut on the internatioal stage at the 2026 AHK Innovation Night, hosted by the German Chamber of Commerce (AHK Greater China). This high-profile event brought together nearly 40 elite tech startups from across China, along with top-tier investors, industry experts, and overseas chambers of commerce, to foster cross-border innovation and commercial collaboration in healthcare.
After rigorous multi-round selection, Jingyin Biotechnology emerged as one of only eight finalists, standing out with its proprietary hard tissue regeneration technology—Infibond. The company’s performance earned widespread acclaim from global delegates, marking a significant milestone in its journey toward becoming a world-class biomedical materials innovator.
A Compelling Story: “The Silent War Inside Us”
During the pitch session, Jingyin Biotechnology delivered a captivating presentation titled “The Silent War Inside Us.” Using an analogy of a collapsing city calling for emergency rescue, the team vividly illustrated the long-standing clinical pain points of traditional bone cement—a market with over 30 million procedures performed globally each year.
The presentation highlighted critical shortcomings of conventional products:
Exothermic peak temperaturecan reach up to 100°C during curing, causing thermal necrosis of surrounding tissues.
Residual monomer contentas high as 3.54%, posing moderate biotoxicity and increasing risks of inflammation, embolism, and severe implantation syndrome.
Clinical mortality rateof 0.6%–1%, imposing heavy burdens on patients and families.
These challenges have persisted for decades, underscoring the urgent need for disruptive innovation—and Jingyin Biotechnology has delivered exactly that.
Infibond: Three Breakthrough Advantages
Jingyin Biotechnology’s independently developed Infibond bone cement achieves a comprehensive technological leap with three core advantages:
Safe Temperature Control– The curing temperature is precisely regulated between 35°C and 40°C, matching human physiological levels and eliminating the risk of thermal injury.
Superior Biosafety– Through optimized material formulation, residual monomer content has been reduced from 3.54% to just 38%, drastically lowering toxicity. Cell attachment rate reaches 99%, demonstrating biocompatibility far exceeding traditional imported products.
World-First Bone Regeneration– By incorporating a unique hydrophilic microsphere structure, Infibond slowly releases space for new bone cell growth after implantation. This allows the material to integrate seamlessly with native bone tissue, achieving true “repair + regeneration” —a paradigm shift from conventional bone cement which only fills defects without promoting regrowth.
Animal experiment data presented at the event confirmed that both first-generation and second-generation Infibond effectively induce new bone formation, validating its regenerative capability.
This original technology has already secured invention patents in China, the United States, and Japan. Moreover, it was selected for the 2025 Ministry of Industry and Information Technology (MIIT) & National Medical Products Administration (NMPA) “Open Competition” program for biomedical materials—the only project in China’s hard tissue bonding field to receive this national-level endorsement.
Expanding Applications Beyond Orthopedics
Infibond is not limited to orthopedics. Its versatile applications span multiple disciplines:
Orthopedics: Spinal repair, joint replacement, and other core procedures, tapping into a multi-billion-dollar bone cement market.
Dentistry & Neurosurgery: Leveraging 3D printing bionic technology to develop novel implant systems and PEEK cranial repair solutions, revolutionizing traditional treatment approaches.
Frontier Technology: In partnership with Sigenics (USA), a world-leading brain-computer interface chip team, Jingyin Biotechnology is contributing to the “Moon Shot” BCI project. The material’s exceptional sealing properties and biocompatibility solve the critical challenge of long-term micro-leakage in implanted chips, laying a safety foundation for next-generation medical devices.
A Milestone Toward Global Leadership
“This is a pivotal moment for Jingyin Biotechnology,” said Xiu Cai, the International Marketing Manager. “We are committed to continuous innovation in biomedical materials, leveraging our proprietary core technologies to bring ‘Created in China’ high-end medical solutions to the world. With our growing global partner network, we aim to lead the transformation of regenerative medicine.”
As the parent company of Beijing OKVD Biological Technology Co., Ltd. , Jingyin Biotechnology’s breakthrough reinforces the combined strength of the Jingyin & OKVD group—offering a complete range of dental and orthopedic consumables backed by world-class R&D.
无尽的精准，永恒的关怀。. The future of bone regeneration has arrived.
